10-K: Brainstorm Cell Therapeutics Navigates Regulatory Hurdles, Outlines Path for Future ALS Trial

Brainstorm Cell Therapeutics withdrew its Biologics License Application (BLA) for NurOwn to treat ALS after an unfavorable advisory committee vote, but is moving forward with plans for a new Phase 3b trial.

Summary

• Brainstorm Cell Therapeutics is focused on developing autologous cellular therapies for neurodegenerative diseases, primarily using its NurOwn technology.
• The company's Phase 3 trial for NurOwn in ALS did not meet statistical significance, leading to the withdrawal of its BLA after a negative advisory committee vote.
• Despite this setback, Brainstorm is committed to the ALS community and is planning a Phase 3b registrational trial, having submitted a Special Protocol Assessment (SPA) request to the FDA.
• The company is also exploring NurOwn's potential in Progressive Multiple Sclerosis (PMS) and Alzheimer's disease (AD), and is researching MSC-NTF derived exosomes for various conditions including ARDS.
• Brainstorm has a comprehensive intellectual property portfolio with 27 granted patents and 23 patent applications worldwide.
• The company has optimized its manufacturing capabilities by leasing a GMP-certified cleanroom at Sourasky Hospital, enhancing its capacity to produce and distribute NurOwn in the EU and Israel.
• Brainstorm has received $15.9 million in grants from the California Institute for Regenerative Medicine (CIRM) and other grants from the National Multiple Sclerosis Society (NMSS) and the ALS Association.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the company's commitment to ALS research, its intellectual property portfolio, and its manufacturing capabilities, the negative aspects such as the failed Phase 3 trial, the withdrawn BLA, and the need for additional funding weigh heavily on the overall sentiment. The company faces significant challenges and uncertainties, which temper any optimism.

Positives

• Brainstorm is actively pursuing a new Phase 3b trial for NurOwn in ALS, demonstrating a commitment to the ALS community.
• The company has a strong intellectual property portfolio with numerous granted patents and applications.
• NurOwn has shown promising biomarker data, indicating a potential for neuroprotection and reduced neuroinflammation.
• The company has optimized its manufacturing capabilities with a GMP-certified cleanroom, enhancing its production capacity.
• Brainstorm has secured significant non-dilutive funding through grants from various organizations.

Negatives

• The Phase 3 trial for NurOwn in ALS did not meet statistical significance, leading to the withdrawal of the BLA.
• The FDA issued a Refusal to File (RTF) letter regarding the BLA, citing issues with substantial evidence of effectiveness and Chemistry, Manufacturing and Controls (CMC).
• An advisory committee voted against the effectiveness of NurOwn for the treatment of mild to moderate ALS.
• The company has a history of losses and expects to incur losses for the foreseeable future.
• The company needs to raise additional capital to continue operations and pursue its business objectives.

Risks

• The company needs to raise additional capital, and failure to do so may force it to restrict or cease operations.
• The company has a history of losses and expects to incur losses for the foreseeable future.
• The company's product development programs are based on novel technologies and are inherently risky.
• The company's NurOwn stem cell therapy may not demonstrate sufficient safety and efficacy to obtain regulatory approval.
• The company faces substantial competition in developing cell therapies for ALS and other neurodegenerative diseases.
• The company is exposed to fluctuations in currency exchange rates, which may impact its operations in Israel.
• Political, economic, and military instability in Israel may impede the company's ability to execute its plan of operations.

Future Outlook

The company is focused on obtaining regulatory approval for NurOwn in ALS and is planning a Phase 3b registrational trial. It is also strategically focused on fully executing the clinical development of NurOwn in PMS and reviewing the optimal approach in AD. The company is also leveraging its pre-clinical data to advance innovative IND-enabling pre-clinical programs in several neurodegenerative diseases.

Management Comments

• Brainstorm remains committed to the ALS Community and is actively exploring the next steps in support of NurOwn, including publication of emerging clinical data and development of a protocol for an additional clinical study.
• The primary objective of the meeting was to discuss plans for a Special Protocol Assessment (SPA) with FDA on the overall protocol design for a planned Phase 3b registrational trial for NurOwn.
• The ultimate goal of the SPA is to secure the FDAs agreement that critical elements of the overall protocol design (e.g., entry criteria, endpoints, planned analyses) are adequate and acceptable for a study intended to support a future marketing application.

Industry Context

The document highlights the challenges and complexities in developing treatments for neurodegenerative diseases like ALS, PMS, and AD. It also reflects the regulatory hurdles and the need for robust clinical data to support approval of novel therapies. The company's focus on autologous cellular therapies and its exploration of exosomes align with current trends in biotechnology and regenerative medicine.

Comparison to Industry Standards

• The company's Phase 3 trial results for NurOwn in ALS did not meet statistical significance, which is a common challenge in ALS drug development, where many trials have failed to meet their primary endpoints.
• The company's decision to withdraw the BLA and pursue a new Phase 3b trial is a strategic move to address the FDA's concerns and improve the chances of regulatory approval, which is a common approach in the pharmaceutical industry.
• The company's focus on biomarker data and its efforts to understand the mechanism of action of NurOwn are consistent with the industry's move towards personalized medicine and targeted therapies.
• The company's partnership with Catalent for manufacturing commercial quantities of NurOwn is a common practice in the biotechnology industry, where companies often rely on contract manufacturing organizations (CMOs) to scale up production.
• The company's exploration of MSC-NTF derived exosomes for ARDS is an innovative approach that aligns with the growing interest in exosome-based therapies in the biotechnology industry.

Legal Proceedings

• A purported shareholder filed a securities class action complaint against the Company and certain of its officers, alleging violations of securities laws.
• Three purported shareholders of the Company filed derivative action complaints against the Company as nominal defendant and certain of its officers, current and former directors, and members of its scientific advisory board, alleging breach of fiduciary duty and unjust enrichment.

Related Party Transactions

• The company has a Research and License Agreement with Ramot, which involves royalty payments and other obligations.
• The company has a subscription agreement with ACCBT Corp., a company under the control of Mr. Chaim Lebovits, which includes rights to acquire additional shares and other rights that could affect the company's ability to raise funds.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional funding and the uncertainty surrounding the success of its clinical trials.
• Employees may experience job insecurity due to the company's financial challenges and strategic realignment.
• Patients with ALS and other neurodegenerative diseases may face delays in accessing potential treatments due to the company's regulatory setbacks and the need for additional clinical trials.
• The company's suppliers and partners may face uncertainty due to the company's financial challenges and strategic realignment.

Next Steps

• The company will submit relevant documentation as outlined by the FDA to support the SPA.
• The company will initiate and complete a Phase 3b trial for NurOwn in ALS.
• The company will continue to explore NurOwn's potential in PMS and AD.
• The company will continue its pre-clinical evaluation of the NurOwn technology platform in other CNS disorders.
• The company will continue to develop its NurOwn exosome-based platform-technology.

Key Dates

Keywords

NurOwn, ALS, Amyotrophic Lateral Sclerosis, Cell Therapy, Neurodegenerative Diseases, Biologics License Application, FDA, Clinical Trial, Mesenchymal Stem Cells, Biomarkers, Progressive Multiple Sclerosis, Alzheimer's Disease, Exosomes, Special Protocol Assessment, Manufacturing